FOR IMMEDIATE RELEASE:
PrimeraDx Names Martin L. Verhoef President and Chief Executive Officer
Mansfield, MA — March 20, 2007 — PrimeraDx today announced that Martin L. Verhoef has been appointed President and Chief Executive Officer effective immediately. Mr. Verhoef will also serve on the Board of Directors and the Nominating Committee.
“We are very pleased with the appointment of Mr. Verhoef since he brings broad experience from the life sciences industry combined with expertise in pioneering molecular diagnostics. I look forward to handing over my duties to him and will continue to support the company as a Director of the Board,” said Kazumi Shiosaki, PhD, a co-founder and acting, interim CEO for PrimeraDx over the past 2 years.
Mr. Verhoef commented, “I am very pleased to join PrimeraDx. I share the Company’s vision of personalized medicine and believe that its proprietary STAR technology will play a major role in this field. The Company has successfully attracted an excellent management team, Board of Directors and Scientific Advisory Board and is poised to contribute to improving healthcare with its products.”
Mr. Verhoef joined PrimeraDx with over 20 years of experience in the Life Sciences industry working for both Fortune 500 companies and start-ups. Mr. Verhoef held various senior management positions at Hewlett-Packard/Agilent in Germany and the US and was with Ciphergen Biosystems, first as Vice President of Sales and Marketing and then as President of the Ciphergen Biosystems Division. During his time at Ciphergen, Mr. Verhoef was instrumental in the transition of the company from an instrumentation business to a company with a diagnostics focus.
Mr. Verhoef began his career in clinical research at the Dijkzigt Academic Hospital and Erasmus University in Rotterdam, The Netherlands, followed by commercial positions with Pharmacia Biotechnologies in The Netherlands and Sweden. He received a BS in Medical Chemistry and a BS in Chemistry from the van ‘t Hoff Institute in Rotterdam, The Netherlands.
PrimeraDx is dedicated to the emerging field of molecular diagnostics. The company is developing multiplexed, quantitative and cost effective assays using its proprietary STAR technology implemented on the ICEPlex instrument platform. STAR combines quantitative PCR with the ability to multiplex up to 60 targets in a single sample. The Company’s initial products are for infectious disease management. PrimeraDx plans to extend its focus into oncology to support cancer therapy management through diagnostic, prognostic, staging and therapeutic monitoring. The Company’s website is: www.primeradx.com.